Amplia is developing two proprietary, orally available, small molecule FAK inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases:
** NCT05355298
Amplia has successfully completed a Phase 1 clinical trial of narmafotinib in healthy volunteers. On the back of positive data from this trial, Amplia is currently conducting a trial of narmafotinib in patients with pancreatic cancer.
Amplia is continuing to evaluate both narmafotinib and AMP886 in a range of preclinical models of cancer and fibrotic disease to identify future development, partnering, and licensing opportunities.